Tenax Therapeutics (TENX) Competitors $5.85 +0.11 (+1.92%) As of 02:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TENX vs. VIRI, ADAG, ORMP, OPTN, HLVX, CCCC, ANIX, COYA, MIST, and GNLXShould you be buying Tenax Therapeutics stock or one of its competitors? The main competitors of Tenax Therapeutics include Virios Therapeutics (VIRI), Adagene (ADAG), Oramed Pharmaceuticals (ORMP), OptiNose (OPTN), HilleVax (HLVX), C4 Therapeutics (CCCC), Anixa Biosciences (ANIX), Coya Therapeutics (COYA), Milestone Pharmaceuticals (MIST), and Genelux (GNLX). These companies are all part of the "pharmaceutical products" industry. Tenax Therapeutics vs. Its Competitors Virios Therapeutics Adagene Oramed Pharmaceuticals OptiNose HilleVax C4 Therapeutics Anixa Biosciences Coya Therapeutics Milestone Pharmaceuticals Genelux Virios Therapeutics (NASDAQ:VIRI) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, community ranking, earnings, institutional ownership, media sentiment and dividends. Which has higher valuation and earnings, VIRI or TENX? Virios Therapeutics is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirios TherapeuticsN/AN/A-$5.30M-$0.27-17.85Tenax TherapeuticsN/AN/A-$7.71M-$2.48-2.36 Which has more volatility & risk, VIRI or TENX? Virios Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Do analysts rate VIRI or TENX? Virios Therapeutics presently has a consensus price target of $3.00, suggesting a potential downside of 37.76%. Tenax Therapeutics has a consensus price target of $17.50, suggesting a potential upside of 199.15%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenax Therapeutics is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Tenax Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the MarketBeat Community prefer VIRI or TENX? Tenax Therapeutics received 143 more outperform votes than Virios Therapeutics when rated by MarketBeat users. Likewise, 54.28% of users gave Tenax Therapeutics an outperform vote while only 50.00% of users gave Virios Therapeutics an outperform vote. CompanyUnderperformOutperformVirios TherapeuticsOutperform Votes350.00% Underperform Votes350.00% Tenax TherapeuticsOutperform Votes14654.28% Underperform Votes12345.72% Do insiders & institutionals believe in VIRI or TENX? 9.1% of Virios Therapeutics shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by insiders. Comparatively, 3.7% of Tenax Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media refer more to VIRI or TENX? In the previous week, Tenax Therapeutics had 1 more articles in the media than Virios Therapeutics. MarketBeat recorded 1 mentions for Tenax Therapeutics and 0 mentions for Virios Therapeutics. Tenax Therapeutics' average media sentiment score of 1.87 beat Virios Therapeutics' score of 0.00 indicating that Tenax Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Virios Therapeutics Neutral Tenax Therapeutics Very Positive Is VIRI or TENX more profitable? Tenax Therapeutics' return on equity of -46.00% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Virios TherapeuticsN/A -130.33% -115.00% Tenax Therapeutics N/A -46.00%-42.65% SummaryTenax Therapeutics beats Virios Therapeutics on 12 of the 16 factors compared between the two stocks. Get Tenax Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TENX vs. The Competition Export to ExcelMetricTenax TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.27M$6.94B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-2.368.7927.2619.97Price / SalesN/A263.06412.06157.64Price / CashN/A65.8538.2534.64Price / Book0.226.597.064.69Net Income-$7.71M$144.20M$3.24B$248.14M7 Day Performance-0.51%3.81%2.56%2.39%1 Month Performance2.45%11.10%8.75%6.06%1 Year Performance78.35%3.95%31.30%13.57% Tenax Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TENXTenax Therapeutics1.6705 of 5 stars$5.85+1.9%$17.50+199.1%+68.7%$24.27MN/A-2.369Positive NewsVIRIVirios TherapeuticsN/A$5.18-2.1%$3.00-42.1%+2,104.8%$99.76MN/A-19.195ADAGAdagene2.7268 of 5 stars$2.09+7.5%$8.00+283.7%-32.0%$98.22M$103.20K0.00260Positive NewsGap DownORMPOramed Pharmaceuticals1.8668 of 5 stars$2.38+1.7%N/A+7.7%$97.22M$2M21.6410Positive NewsOPTNOptiNose1.8038 of 5 stars$9.60flat$9.00-6.3%N/A$97.22M$81.86M-2.29190HLVXHilleVax3.2541 of 5 stars$1.93+3.2%$3.00+55.4%-86.7%$96.77MN/A-0.6220Positive NewsCCCCC4 Therapeutics2.2236 of 5 stars$1.33+6.4%$12.00+802.3%-68.7%$94.44M$39.78M-0.78150Positive NewsGap UpANIXAnixa Biosciences3.4607 of 5 stars$2.89+12.5%$9.00+211.4%+30.2%$93.05M$210K-7.415Analyst ForecastHigh Trading VolumeCOYACoya Therapeutics2.2217 of 5 stars$5.55+4.1%$17.00+206.3%-29.6%$92.82M$3.69M-8.546News CoveragePositive NewsAnalyst ForecastMISTMilestone Pharmaceuticals2.3989 of 5 stars$1.73+6.8%$17.00+882.7%+19.4%$92.49M$1M-2.1430Positive NewsGap UpGNLXGenelux1.2226 of 5 stars$2.45+1.2%$17.75+624.5%+7.7%$92.45M$8K-2.5810News CoverageGap Down Related Companies and Tools Related Companies Virios Therapeutics Alternatives Adagene Alternatives Oramed Pharmaceuticals Alternatives OptiNose Alternatives HilleVax Alternatives C4 Therapeutics Alternatives Anixa Biosciences Alternatives Coya Therapeutics Alternatives Milestone Pharmaceuticals Alternatives Genelux Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TENX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenax Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TENX Stock Free TENX Stock Alerts